GILEAD SCIENCES, INC. 4

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of Gilead common stock for roughly $390K under a Rule 10b5-1 plan.

On July 15, 2026, Gilead Sciences, Inc. Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of Gilead common stock at an average price of approximately $129.93 per share, for proceeds of about $389,777, under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this transaction, Dickinson beneficially owns 168,646 shares of Gilead common stock. The sale prices for the reported transactions ranged between $129.45 and $130.08 per share, and detailed breakdowns by execution price are available from the company or the SEC upon request.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001310204-26-000022

Alert Tier

8